Newsroom

- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...

High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease By Eleanor Malone March 1, 2022 Executive Summary Evolving challenges...

- OnQuality will present an update on its NOVA-II Phase 2 clinical trial investigating OQL011, a proprietary ointment designed to treat...

Written by Alex Philippidis February 2, 2022 OnQuality recently announced positive news for its lead candidate OQL011, an ointment...

Written by Michael McCullar, Ph.D. Feb. 1, 2022 The ability to differentiate in a competitive marketplace lies in developing key...

Full Title: OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea...

Mark Terry January 10, 2022 https://www.biospace.com/article/-clinical-catch-up-january-3-7 The biopharma industry has started 2022 with...

Heather McKenzie January 10, 2022 https://www.biospace.com/article/executive-perspectives-on-2022-/ After a decade of breakthroughs in...

By Sara Karlovitch OQL011, for cancer therapy induced skin toxicity, demonstrated a tolerable safety and acceptable efficacy profile,...